BioTech

Bayer Announces Approval Of New Indication For Kerendia In The EU

March 30, 2026 — 02:58 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Bayer (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE) announced that the European Commission has granted approval in the European Union for Kerendia or finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist for the treatment of adults with heart failure with left ventricular ejection fraction =40%. In the EU, Kerendia is now indicated for the treatment of symptomatic chronic heart failure with LVEF =40% in adults, expanding its use beyond the existing indication in patients with chronic kidney disease associated with type 2 diabetes.

The approval by the European Commission is based on the positive results from the pivotal Phase III FINEARTS-HF study.

At last close, Bayer shares were trading at 38.26 euros.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech

Latest Articles
Data is currently not available